Navigation Links
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Date:12/10/2007

-Patients treated with Lovenox(R) (enoxaparin sodium injection) were also

less likely to be readmitted to hospital within 90 days-

BRIDGEWATER, N.J., Dec 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the results of a study that demonstrated total hospital direct medical costs associated with VTE treatment are reduced by $550 per patient when they were treated with the use of low-molecular weight heparin (LMWH) vs. unfractionated heparin (UFH) with 97.3% of LMWH patients receiving Lovenox. Patients who received LMWH were also less likely to be readmitted to the hospital with a VTE recurrence within 90 days. The findings were presented at American Society of Hematology Annual Meeting (ASH) in Atlanta, GA.

The current healthcare and economic burden of venous thromboembolism (VTE) in U.S. hospitals is significant. In patients with confirmed VTE, evidence- based guidelines recommend treatment for a minimum of five days with either a low-molecular weight heparin (LMWH, such as Lovenox) or UFH. However, in the real-world practice, the total hospital direct medical costs and VTE-related readmission rates of these VTE treatment regimens are not clear.

A retrospective real-world cohort study examining discharge and billing records from the Premier Perspective(TM) database included discharges of patients less than 18 years old and with a primary diagnosis of VTE from January 2003 through June 2005. Only VTE patients who were treated with either LMWH or UFH were included in the study. Total hospital direct medical costs associated with VTE treatment (including drug costs, hospital costs, and professional costs) were quantified and compared for patients receiving UFH and LMWH. Furthermore, VTE-related readmission rates at days 30 and 90 post- discharge were compared for both patient cohorts. Total direct medical costs (US $) were compared using multivariate statistics, adjusting for patient and hospital characteristics. Logistic
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... SAN DIEGO, Oct. 28 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... 30, 2009. For the third quarter of 2009, the Company reported ... with a net loss of $17.7 million, or $0.46 per share, ... September 30, 2009, the Company reported a net loss of $43.1 ...
... BATESVILLE, Ind., Oct. 28 Hill-Rom Holdings, Inc. (NYSE: ... and 2010 financial guidance on Wednesday, November 11, 2009. ... morning on Thursday, November 12, 2009 at 7:30 a.m. EST. ... Quarter Earnings and 2010 Financial Guidance release will be issued ...
Cached Medicine Technology:Neurocrine Biosciences Reports Third Quarter 2009 Results 2Neurocrine Biosciences Reports Third Quarter 2009 Results 3Neurocrine Biosciences Reports Third Quarter 2009 Results 4Neurocrine Biosciences Reports Third Quarter 2009 Results 5Neurocrine Biosciences Reports Third Quarter 2009 Results 6Neurocrine Biosciences Reports Third Quarter 2009 Results 7Neurocrine Biosciences Reports Third Quarter 2009 Results 8Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 2
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... Blood ... Pressure Up to 30 Points, ... that the United States Food and Drug Administration (FDA),has approved ... known as high blood pressure. AZOR is a,convenient, once daily, ...
... to be higher than for whites, study finds , , THURSDAY, ... diabetes who take drugs to control their disease are less ... a new study finds. , Two factors appear to account ... to medications and emotional responses to having diabetes, according to ...
... QMED ) today announced it expects to report for ... of approximately $10.8 million and,$26.6 million and a net ... cash position as of August 31st, 2007 is,approximately $6.4 ... and CEO, said, "During the months of July and,August, ...
... the Largest and the ... Becomes McLaren,s Newest Subsidiary in Southeast ... Michigan, PONTIAC, Mich., Sept. ... care system in Michigan,McLaren Health Care is pleased to announce the addition of POH ...
... PARIS, Sept. 27 KARL LAGERFELD SAS announced ... to create KARL,LAGERFELD men,s and women,s eyewear starting ... one of the most prominent eyewear companies,the exclusive ... sun and ophthalmic collections for the KARL LAGERFELD ...
... WASHINGTON, Sept. 27 - 100 Black Men of,America, Inc. ... that,will work to increase local outreach to diverse communities ... to enhance,delivery of services to diverse communities during times ... the agreement the Red Cross will provide disaster training ...
Cached Medicine News:Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 2Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 3Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 4Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 6Health News:Older Blacks, Latinos Struggle With Diabetes Control 2Health News:Older Blacks, Latinos Struggle With Diabetes Control 3Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 3Health News:McLaren Health Care Adds POH Medical Center to System 2Health News:KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc. 2Health News:100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: